Quality control
To assess the quality of included studies, three investigators (W.Y, M.L and Y.Q.L) independently examined the randomization procedure, estimation of sample size, adoption of blind in study design, allocation concealment, if the intention-to-treat analysis being followed, loss to follow-up and dropout. Jadad/Oxford quality scoring system was adopted to quantify study quality [1] . Any discrepancies would be solved by consensus.
Data extraction
Another three investigators (Y.B.S, D.K.C and Y.Q.L) reviewed the included studies and extracted the data independently. Data on study design, study time, number of patients in each arm, staging information, randomization scheme, follow-up duration, treatment protocol, endpoints and failure patterns were abstracted. Any discrepancies in quality assessment and data extraction were solved by consensus.
Statistical analysis
The primary end-point was OS, defined as the duration from randomization to death from any cause. Second endpoints included progression-free survival (PFS, defined as time from randomization to the first occurrence of disease progression) and objective response (complete response, partial response, stable disease, progressive disease).
Survival data were expressed as hazard ratio (HR) and objective response as odds ratio (OR). HR and its variance were directly extracted from the original text. OR and its variance were calculated through the number of responders (complete response + partial response) and non-responders (stable disease + progression disease) in each treatment arm. Traditional direct meta-analysis was conducted first using Stata 13.0 (StataCorp LP, College Station, TX, USA). We calculated the pooled estimates of HRs or ORs and corresponding 95% confidence intervals (CIs) of direct comparisons between two therapeutic regimens. A two-sided P-value of < 0.05 was considered significant. Heterogeneity across studies was tested by χ 2 test and I 2 statistic along with a forest plot. Statistically significant heterogeneity was defined as a χ 2 P-value < 0.1 or an I 2 statistic > 50%.
The network meta-analysis was planned in the R software (version 3.3.3; R Foundation, Vienna, Austria) using the netmeta package [2, 3] and frequentist approach [2] . Logarithmic of HR (logHR) or OR (logOR) and its variance (selogHR or selogOR) would be prepared for statistical data analysis of network meta-analysis.
Treatment effects were estimated by HRs or ORs with corresponding 95% confidence intervals (CIs). Heterogeneity or inconsistency between and within designs was
established by Q test which was proposed by Rücker et al. [2] to be a generalization of Cochran's test. No heterogeneity existed if P > 0.1, and fixed-effects model would be used. In case of significant heterogeneity, the use of random-effects model and the performance of sensitivity analysis would be considered. Forest plots of network meta-analysis were obtained using anti-PD-1, anti-PD-L1 and docetaxel as the reference group, respectively. A P-score, proposed by Rücker and Schwarzer [4] as a frequentist analog to surface under the cumulative ranking curve [5, 6] would be adopted to rank the treatment arms. P-score would be 100% for the best treatment and 0% for the worst treatment. Overall grade 3-5 toxicities were compared using the χ 2 test and a two-sided P-value of < 0.05 was considered significant. Survival and objective response analysis were conducted in intention-to-treat population and toxicity comparison in patients receiving at least one dose of treatment. 
